{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-040194","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.695504+00:00","generated_at":"2026-05-22T10:58:05.898361+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC BioPharma regains Nasdaq compliance after equity shortfall notice","bullets":["On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).","On May 5, 2025, Nasdaq confirmed compliance after ABVC's Q1 2025 10-Q showed equity of $7,956,295, closing the matter.","The company avoided delisting by demonstrating equity above the required minimum through its quarterly filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-040194","json":"https://secwatch.observer/filing/0001213900-25-040194.json","markdown":"https://secwatch.observer/filing/0001213900-25-040194.md","text":"https://secwatch.observer/filing/0001213900-25-040194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025040194/0001213900-25-040194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025040194/ea0240961-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:58:05.898361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}